Nektar Therapeutics Reports Pfizer Inc. Announcement That New Studies Show More Than Half Of Patients At Risk For Or Suffering From Complications Of Type 2 Diabetes Delay Insulin Injections; Some More Than Four Years

WASHINGTON--(BUSINESS WIRE)--June 12, 2006--Nektar Therapeutics (Nasdaq:NKTR - News): Nektar Therapeutics (Nasdaq:NKTR - News) reported today that Pfizer announced the results from two new studies that show many people with type 2 diabetes who should take insulin injections to improve blood sugar control often choose to avoid injections for at least four years or more, despite insulin’s proven effectiveness. These data were presented today at the 66th Annual Scientific Sessions of the American Diabetes Association.